Muscle Biology and Exercise Physiology

Introduction to Muscle Biology

Skeletal muscle comprises approximately 30-40% of body mass in adults and is one of the most metabolically plastic tissues—capable of profound remodelling in response to exercise, inactivity, ageing, and disease. Skeletal muscle performs mechanical work (locomotion, posture, breathing), maintains metabolic health (the largest insulin-responsive tissue), produces myokines with systemic endocrine effects, and stores amino acid reserves mobilised during fasting or illness. Understanding muscle biology is essential for treating muscular dystrophies and myopathies, preventing age-related sarcopenia, optimising athletic performance, and understanding metabolic diseases where muscle dysfunction plays a central role.

Muscle cells (myofibers) are post-mitotic multinucleated syncytia formed by fusion of myoblasts during development. Each myofiber contains thousands of myofibrils—longitudinal bundles of sarcomeres (the contractile unit). The sarcomere contains thick filaments (myosin) interdigitating with thin filaments (actin + troponin + tropomyosin) anchored at Z-discs; cross-bridge cycling between myosin heads and actin generates mechanical force. Myosin isoforms (MyHC-I slow-oxidative in type I fibres; MyHC-IIa and IIx fast-oxidative and fast-glycolytic in type IIa and IIx fibres) determine fibre type contractile properties and metabolism, and are modulated by exercise training and neuromuscular activity.

Muscle Contraction

Excitation-Contraction Coupling

Muscle contraction initiated by motor neuron firing proceeds through excitation-contraction (EC) coupling. Acetylcholine released at the neuromuscular junction binds AChR depolarising the sarcolemma; action potential propagates along the T-tubule system; voltage-gated DHPR (CaV1.1) on T-tubules mechanically activates RYR1 (ryanodine receptor 1) on the sarcoplasmic reticulum (SR) releasing Ca2+ (~10-fold from 100 nM to 1-10 microM in the cytoplasm). Ca2+ binds troponin C on thin filaments, causing tropomyosin conformational shift exposing myosin binding sites on actin; cross-bridge cycling (ATP hydrolysis powering myosin head conformational changes) generates force. Ca2+ is resequestered by SERCA1 (fast-twitch) or SERCA2a (cardiac/slow-twitch) completing relaxation. RYR1 and DHPR mutations cause malignant hyperthermia and central core disease.

Muscle Fibre Type Diversity

Human skeletal muscle fibres are broadly classified by myosin heavy chain isoform: Type I (MyHC-I, slow, mitochondria-rich, oxidative, highly fatigue-resistant, sustained aerobic activity), Type IIa (MyHC-IIa, fast-oxidative, mixed), and Type IIx (MyHC-IIx, fast-glycolytic, powerful but rapidly fatiguing, explosive short-duration activity). Hybrid fibres co-expressing two MyHC isoforms arise during fibre type transition. The transcriptional regulator calcineurin-NFAT drives type I gene expression; PGC1-alpha promotes mitochondrial biogenesis and oxidative capacity. Endurance training shifts IIx → IIa → I composition and increases mitochondrial density; resistance training hypertrophies existing fibres through mTORC1 activation driving ribosome biogenesis and protein synthesis. Elite marathon runners have 70-80% type I fibres; elite sprinters have 70-80% type IIx.

Muscle Regeneration

Satellite Cells

Muscle satellite cells (SCs) are quiescent, Pax7-expressing adult muscle stem cells residing under the basal lamina of myofibers. After injury, SCs activate (losing quiescence, upregulating Myf5 and MyoD), proliferate extensively, and either differentiate (fusing to repair damaged fibres or forming new myotubes) or self-renew restoring the satellite cell pool. Notch signalling maintains quiescence; activating SC requires HGF, FGF, and Wnt signalling from the niche. In muscular dystrophies, repeated degeneration-regeneration cycles exhaust the satellite cell pool; SC transplantation and gene therapy strategies aim to replenish both the satellite cell pool and the corrected gene expression. With ageing, SC ability to regenerate declines—due to reduced Notch activation, increased Wnt signalling driving fibrosis over myogenesis, and oxidative stress.

Muscle Diseases

Duchenne muscular dystrophy (DMD) is caused by dystrophin gene mutations (X-linked, 1 in 3500 male births) causing complete dystrophin loss—progressive muscle wasting, cardiorespiratory failure, eventual death in early adulthood without intervention. Dystrophin connects the actin cytoskeleton to the extracellular matrix via the dystrophin-associated protein complex (DAPC), providing mechanical stability during contraction; its absence causes sarcolemmal mechanical failure, calcium influx, necrosis, and inflammation. Exon-skipping ASOs (eteplirsen skips exon 51 restoring >10% dystrophin), micro-dystrophin gene therapy (AAV9 delivering truncated functional dystrophin to all muscle), and CRISPR deletion of exon 51 have shown dystrophin restoration in clinical trials—transforming the treatment landscape for this previously incurable disease.

Examples and Applications

Example 1: AAV Gene Therapy for DMD

Micro-dystrophin AAVrh74 gene therapy (delandistrogene moxeparvovec, SRP-9001) delivered systemically restores truncated but functional dystrophin to essentially all muscle groups simultaneously. Early Phase I/II data in DMD boys showed 40-80% of normal dystrophin protein expression in biopsies and clinically meaningful functional improvements. FDA accelerated approval in 2023 (first DMD gene therapy) applied to ambulatory patients aged 4-5, with post-marketing confirmatory trial required. Challenges include immune reactions to AAV capsid requiring immunosuppression, potential re-dosing challenges due to anti-AAV immunity, and limited data in older less-ambulatory patients. Durable efficacy requires that systemically delivered mini-dystrophin persists in the differentiated, post-mitotic myofibers for years to decades.

Example 2: Exercise Biochemistry

Endurance exercise activates AMP kinase (AMPK) from falling ATP/AMP ratio, stimulating fatty acid oxidation, GLUT4 translocation improving glucose uptake, and PGC1-alpha translocation to the nucleus activating mitochondrial biogenesis genes (TFAM, NRF1/2). Resistance exercise activates mTORC1 through PI3K-Akt (from IGF-1 signalling) and amino acid sensing via Rag GTPases, driving protein synthesis and muscle hypertrophy. Post-exercise, the 30-60 minute 'anabolic window' of elevated AMPK and mTORC1 (from amino acid consumption of leucine particularly) represents optimal protein synthesis timing. These molecular pathways explain training adaptations and inform clinical exercise prescriptions for metabolic disease, sarcopenia prevention, and cancer cachexia treatment.

Example 3: Myostatin and Muscle Growth

Myostatin (GDF-8, TGF-beta superfamily member) is secreted by muscles as an autocrine inhibitor of muscle growth. Myostatin null mice have doubled muscle mass; Belgian Blue and Piedmontese cattle with natural myostatin loss-of-function mutations have ~20-30% more muscle mass (double muscling). A human child with myostatin pathway mutations (propeptide region freeing myostatin) showed extraordinary muscle development while being otherwise healthy. Myostatin inhibitors (anti-myostatin antibodies: landogrozumab; ActRIIA/B inhibitors: luspatercept) were developed for muscle diseases and cancer cachexia. ActRIIB pathway inhibition also blocks other TGF-beta superfamily members (GDF-11, Activin A) limiting selectivity; combination strategies are in development.

Example 4: Sarcopenia Biology

Sarcopenia—age-related loss of muscle mass and function—affects approximately 10-15% of elderly individuals and is defined using combined criteria of low muscle mass plus low strength or physical performance. Mechanisms include reduced satellite cell number and function, increased inflammatory cytokines (IL-6, TNF—'inflammaging'), mitochondrial dysfunction in ageing myofibers, reduced anabolic hormone levels (IGF-1, testosterone, oestrogen), neuromotor unit remodelling, reduced PI3K/mTOR anabolic signalling, and reduced physical activity creating a vicious cycle. Testosterone and selective androgen receptor modulators (SARMs) increase muscle mass; combination resistance exercise + protein supplementation (leucine-rich proteins at 1.2-1.6 g/kg/day) is the most evidence-based intervention preventing and partially reversing sarcopenia.

Example 5: Malignant Hyperthermia

Malignant hyperthermia (MH) is a life-threatening pharmacogenetic crisis triggered by volatile anaesthetics (halothane, sevoflurane) or succinylcholine in susceptible individuals with RYR1 mutations. Mutant RYR1 opens excessively upon anaesthetic-induced depolarisation causing massive Ca2+ release, uncontrolled myosin-actin cycling, ATP depletion, and temperature rises of up to 1°C/5 minutes. Without treatment (dantrolene—RYR1 blocker IV), mortality exceeds 70%; with early dantrolene and supportive care it is below 5%. MH susceptibility testing by in vitro contracture test (IVCT) or genetic RYR1/CACNA1S screening identifies at-risk patients before anaesthesia. Approximately 1 in 15,000-50,000 anaesthetics trigger MH in unscreened patients.

Example 6: Myokines as Exercise Hormones

Contracting muscles produce and release myokines—signal proteins mediating local and systemic effects of exercise. IL-6 is released by exercising muscles into the circulation, acting on liver to stimulate gluconeogenesis, on fat to promote lipolysis. Irisin (cleaved from FNDC5, PGC1-alpha target gene) browning white adipocytes, improving bone density and brain neuroplasticity. Musclin (OSTN, osteocrin) enhances endurance exercise capacity by increasing natriuretic peptide availability. BDNF produced by exercising muscles mediates cognitive benefits of exercise. Meteorin-like (Metrnl) recruits immune cells driving adipose tissue beiging. These exercise hormones explain the systemic health benefits of muscle contraction beyond local fuel consumption—brain, adipose, bone, liver, and immune function all respond to circulating myokines.

Example 7: Mitochondrial Diseases Affecting Muscle

Mitochondrial myopathies present with exercise intolerance, weakness, and elevation of lactate with exertion. MELAS (mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes) affects the m.3243A>G tRNA mutation; MERRF (myoclonic epilepsy with ragged red fibres) carries m.8344A>G. Ragged red fibres on Gomori trichrome stain represent subsarcolemmal mitochondrial accumulation in affected muscle fibres. Nuclear gene mutations in mitochondrial OXPHOS assembly factors cause Leigh syndrome and other severe paediatric myopathies. Treatment remains symptomatic; clinical trials of EPI-743 (idebenone, Complex I bypass), KAT6A acetyl-CoA boosting NAD+ metabolism, and AAV gene therapy for NADH dehydrogenase subunits are in early phase.

Example 8: Cardiac Muscle vs. Skeletal Muscle

Cardiac muscle (myocardium) shares sarcomere structure with skeletal muscle but differs fundamentally: cardiac myocytes are mononucleate, branched cells connected by intercalated discs containing gap junctions (enabling electrical synchronisation for coordinated contraction) and adherens junctions (mechanical coupling). Cardiac muscle is exclusively type I-equivalent slow oxidative; it cannot tolerate the ATP debt of anaerobic glycolysis that skeletal muscle uses for short-duration explosive exercise. Calcium handling differs—cardiac EC coupling requires Ca2+ influx through L-type CaV1.2 channels triggering SR CICR (Ca2+-induced Ca2+ release via RYR2)—reflecting the need for graded force adjustment through tuning Ca2+ influx. Mutations in RYR2, TNNI3, MYH7, and 30+ sarcomere genes cause hypertrophic cardiomyopathy and arrhythmias—directly implicating fundamental muscle biology in cardiovascular disease.

Try it live

Everything above runs in your browser — open Sliding Filament & Muscle Fiber Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.